The second group consists of carcinoma in situ (CIS), a high-grade lesion characterized by TP53 and p21 mutations with a 60-80% progression rate to invasive disease involving RB and p16 (T1-T4) [2]. This evidence concerns the gene CDKN2A and in situ carcinoma.